| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
SpyGlass Pharma, Inc.$22.52
+2.45 (+12.21%)
D 34Pipeline Score Overvalued Biotech · Clinical
Market Cap
696.75 M
EPS
-
P/E Ratio
-
Value Trade
877.00 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
8.54 M
Operating CF
-13.54 M
Total Assets
258.39 M
Total Liabilities
8.27 M
Equity
250.11 M
D/E Ratio
12,345
-4.84 %
Week
-15.8 %
1 Month
-29.74 %
3 Month
-17.47 %
6 Month
-17.47 %
5 Year
-17.47 %
All Time
Cash Data
Cash Position
238.90 M
Monthly Burn
4.51 M
Runway
51.2 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
169.49 K
52 Week Range
20.15 - 30.56
% held by Insiders
58.27 %
% held by Institutions
38.29 %
Enterprise Value
447.36 M
Total Shares
33.33 M
Short %
22.1 %
Float Shares
5.93 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D34
Pipeline Score $290M
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.4x
rNPV / MCap Top 44%
Micro Cap (rank 511 of 911)
Percentile RankSpyGlass Pharma, Inc. faces pipeline headwinds (34/100), with $724M risk-adjusted pipeline value, led by Bimatoprost System in Cataract (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bimatoprost System Small molecule | Cataract | Phase 3 | NCT06120842 | 43% | $665M | ACTIVE NOT_RECRUITING | 1,001 | AVERAGE | B (63) | Nov 1, 2027 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
BIM-IOL System | open-angle glaucoma (OAG) or ocular hypertension (OHT) | Phase 1/2 | 2026-05-14 | In the Phase 1/2 trial of the BIM-IOL System, 98% of participants were free from topical IOP-lowering medications, achieving a mean IOP reduction of 34% from baseline at a dose of 78-mcg, with all patients reaching a best-corrected distance visual acuity of 20/32 or better. Read More | SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates Read More | |
BIM-IOL System | open-angle glaucoma (OAG) or ocular hypertension (OHT) | Phase 1/2 | 2026-05-14 | In the Phase 1/2 trial of the BIM-IOL System, 98% of participants were free from topical IOP-lowering medications, achieving a mean IOP reduction of 34% from baseline at a dose of 78-mcg, with all patients reaching a best-corrected distance visual acuity of 20/32 or better. Read More | SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates Read More | |
BIM-IOL System | open-angle glaucoma (OAG) or ocular hypertension (OHT) | Phase 1/2 | 2026-05-14 | In the Phase 1/2 trial of the BIM-IOL System, 98% of participants were free from topical IOP-lowering medications, achieving a mean IOP reduction of 34% from baseline at a dose of 78-mcg, with all patients reaching a best-corrected distance visual acuity of 20/32 or better. Read More | SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SGP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SGP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SGPSpyGlass Pharma Appoints Shannon Treviño as General Counsel
SpyGlass Pharma has appointed Shannon Treviño as General Counsel, bringing significant legal expertise to the company. Treviño's background includes leadership roles in corporate law and successful navigation of major acquisitions. Her appointment coincides with the advancement of SpyGlass's BIM-IOL System through Phase 3 clinical trials, aiming for potential commercialization.
Read more →SGPSpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
SpyGlass Pharma has appointed Mike Pinder as Vice President of Marketing, leveraging his extensive experience in ophthalmology. Pinder will lead marketing efforts as the company advances its BIM-IOL System through Phase 3 clinical trials. His background includes successful brand launches, which are expected to support the commercialization of the innovative drug delivery technology.
Read more →SGPSpyGlass Pharma to Participate in Upcoming Investor Conferences
SpyGlass Pharma, a late-stage biopharmaceutical company, announced its participation in several upcoming investor conferences, including the Stifel 2026 Virtual Ophthalmology Forum and the Jefferies Global Healthcare Conference. These events will feature presentations by the executive management team, highlighting the company's innovative drug delivery solutions for chronic eye conditions. Access to live webcasts will be available on their website.
Read more →SGPSpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
SpyGlass Pharma reported its Q1 2026 financial results, highlighting positive topline data from its Phase 1/2 trial of the BIM-IOL System, which showed significant intraocular pressure reduction. The company is on track to complete enrollment in its Phase 3 trials by 2027 and has a strong cash position to fund operations through 2028. The CEO emphasized the potential benefits of the BIM-IOL System for glaucoma patients.
Read more →SGP▼ -10.3%on this news
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
SpyGlass Pharma reported its fourth quarter and full year 2025 earnings, highlighting the initiation of two Phase 3 trials for its BIM-IOL System. The company achieved positive results in its Phase 1/2 trial, showing significant intraocular pressure reduction. Despite a net loss of $39.9 million, SpyGlass is well-funded following its IPO, which positions it for future growth.
Read more →SGPSpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
SpyGlass Pharma announced positive results from its Phase 1/2 trial of the BIM-IOL System, showing significant reductions in intraocular pressure (IOP) and improved visual acuity in patients with open-angle glaucoma or ocular hypertension. The trial demonstrated that 97% of patients were free from topical IOP-lowering medications after 12 months. Safety results were comparable to standard cataract surgery, indicating the system's potential for long-term treatment adherence.
Read more →SGPamended. All statements in this press release that are not purely historical are forward-looking statements, including, but not limited to, statements regarding the potential benefits and impact of the BIM-IOL System on
SpyGlass Pharma announced positive 12-month results from its Phase 1/2 trial for the BIM-IOL System, indicating it effectively reduces elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The trial included 104 patients, and results showed 97% were off all topical IOP-lowering medications, with 100% reaching at least 20/32 vision. Safety results were comparable to traditional cataract surgery, with no serious adverse events reported. The company is focused on advancing further trials towards potential commercial approval.
Read more →SGPSpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit
SpyGlass Pharma, a late-stage biopharmaceutical company, will host one-on-one meetings at the Jefferies Biotech on the Beach Summit in Miami Beach on March 11, 2026. The company aims to improve treatment for chronic eye conditions through its innovative drug delivery platform, which utilizes approved medicines. Founded in 2019, SpyGlass Pharma focuses on durable solutions for eye care.
Read more →SGP▲ +6.3%on this news
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
SpyGlass Pharma has announced the successful closing of its initial public offering, raising $172.5 million by offering 10,781,250 shares at $16.00 each. This includes the full exercise of the underwriters' option to purchase additional shares. The company's stock began trading on Nasdaq under the ticker SGP on February 6, 2026.
Read more →SGPSpyGlass Pharma Announces Pricing of Initial Public Offering
SpyGlass Pharma has announced the pricing of its initial public offering, offering 9,375,000 shares at $16.00 each, aiming to raise around $150 million. The IPO is set to close on February 9, 2026, and the shares will begin trading on the Nasdaq Global Select Market on February 6, 2026. The company focuses on innovative treatments for chronic eye conditions.
Read more →Competitive Position
How SGP ranks across every disease it competes inCompetitive Position is a premium feature
See how SGP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial